Detailed Information

Cited 12 time in webofscience Cited 11 time in scopus
Metadata Downloads

A comparative study of DA-9601 and misoprostol for prevention of NSAID-associated gastroduodenal injury in patients undergoing chronic NSAID treatmentopen access

Authors
Lee, Oh YoungKang, Dae-HwanLee, Dong HoChung, Il-KwunJang, Jae-YoungKim, Jin-IlCho, Jin-WoongRew, Jong-SunLee, Kang-MoonKim, Kyoung OhChoi, Myung-GyuLee, Sang-WooLee, Soo-TeikKim, Tae-OhShin, Yong-WoonSeol, Sang-Yong
Issue Date
Oct-2014
Publisher
PHARMACEUTICAL SOC KOREA
Keywords
DA-9601(Stilen (R)); Misoprostol; NSAID-associated; Gastroduodenal injury
Citation
ARCHIVES OF PHARMACAL RESEARCH, v.37, no.10, pp.1308 - 1316
Indexed
SCIE
SCOPUS
KCI
Journal Title
ARCHIVES OF PHARMACAL RESEARCH
Volume
37
Number
10
Start Page
1308
End Page
1316
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/8931
DOI
10.1007/s12272-014-0408-3
ISSN
0253-6269
Abstract
Misoprostol is reported to prevent non-steroidal anti-inflammatory drug (NSAID)-associated gastroduodenal complications. There is, however, limited information regarding the efficacy of DA-9601 in this context. We performed a comparative study on the relative efficacy of DA-9601 and misoprostol for prevention of NSAID-associated complications. In this multicenter, double-blinded, active-controlled, stratified randomized, parallel group, non-inferiority trial, 520 patients who were to be treated with an NSAID (aceclofenac, 100 mg, twice daily) over a 4-week period were randomly assigned to groups for coincidental treatment with DA-9601 (60 mg, thrice daily) (236 patients for full analysis) or misoprostol (200 mu g, thrice daily) (242 patients for full analysis). A total of 236 patients received DA-9601 and 242 received misoprostol. The primary endpoint was the gastric protection rate, and secondary endpoints were the duodenal protection rate and ulcer incidence rate. Endpoints were assessed by endoscopy after the 4-week treatment period. Drug-related adverse effects, including gastrointestinal (GI) symptoms, were also compared. At week 4, the gastric protection rates with DA-9601 and misoprostol were 81.4 % (192/236) and 89.3 % (216/242), respectively. The difference between the groups was -14.2 %, indicating non-inferiority of DA-9601 to misoprostol. Adverse event rates were not different between the two groups; however, the total scores for GI symptoms before and after administration were significantly lower in the DA-9601 group than in the misoprostol group (-0.2 +/- A 2.8 vs 1.2 +/- A 3.2; p < 0.0001). DA-9601 is as effective as misoprostol in preventing NSAID-associated gastroduodenal complications, and has a superior adverse GI effect profile.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Lee, Sang Woo photo

Lee, Sang Woo
안산병원 (Department of Gastroenterology and Hepatology, Ansan Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE